ArticleClinical, cosmetic and investigational dermatology2026
A Real-World Retrospective Cohort Study Evaluating Clinical Effects and Safety of Radiofrequency Microneedling for the Treatment of Rosacea.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiofrequency Microneedling (RFMN) targets vascular, inflammatory, and dermal remodeling pathways in rosacea; however, evidence from routine practice remains limited. Objective: To evaluate the clinical effects and safety of POTENZA Methods: We conducted a retrospective cohort study of 50 adults with clinically diagnosed rosacea treated with RFMN at a dermatology center (Hallym University Kangnam, Seoul, Republic of Korea). Severity was assessed longitudinally using the Rosacea Area and Severity Index (RASI) and erythema index from standardized photographs and the medical records. Missing data were addressed using multiple imputation and linear mixed-effects models. A substantial proportion of patients (68%) received concomitant oral antibiotics, and severity scoring relied on retrospective evaluation of photographs and medical records. Safety outcomes included adverse events, pain scores, lesion fading, texture improvement, and patient-reported satisfaction. Results: Fifty patients (80% women; median age, 33 years) were included. The median rosacea duration was 54 months (IQR 24-81), and most had Fitzpatrick phototype III (76%). Missingness was consistent with a missing-at-random mechanism, as patients lost to follow-up had lower baseline disease severity. The mean RASI decreased from 11.9 to 9.08 (difference -2.79; 95% CI -3.48 to -2.11; p<0.001). The mean erythema index decreased from 2.48 to 1.58 (difference -0.90; 95% CI -1.14 to -0.66; p<0.001). Lesion fading occurred in 80% of the patients, and texture improvement occurred in 72%. Mild adverse events occurred in three patients (6%) and resolved within 96 hours. Conclusion: RFMN (POTENZA®) was associated with significant longitudinal improvements in rosacea severity and erythema, with favorable tolerability. Given the retrospective design, concomitant antibiotic use, and photographic scoring, these findings should be considered hypothesis-generating and warrant confirmation in prospective controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.